Partnerships & Business Development

Partnering with innovative researchers, manufacturers and technology companies across the pharmaceutical life cycle is at the core of our strategic plan. We are always looking for opportunities to enhance the value of our technology platform and to advance the possibilities of pharmaceutical product development. Like us, our partners and allies are dedicated to enhancing their customers' experiences.

Both our business model and our partner-centric culture align with these strategic relationships. Our 3DP for Pharma platform grew out of an exclusive licensing agreement with the Massachusetts Institute of Technology’s (MIT) 3DP process for pharmaceutical research and development. After successfully negotiating FDA approval of SPRITAM (levetiracetam) Tablet(s) for Oral Suspension, the first prescription drug product that is manufactured using the 3DP and ZipDose® Technology, we remain committed to bringing our proprietary ZipDose® Technology to the market in partnership with like-minded innovators.

If you are interested in business development R&D pharma or investment partnership opportunities with Aprecia, please contact us.

Contact us

EARLY STAGE SOLUTIONS ACCELERATE TIME-TO-MARKET

From early-stage development to late-stage commercialization, our 3DP technologies provide formulation and manufacturing solutions that translate more quickly to final product scale, bringing significant business advantages to your bottom line.

Use breakthrough dosage form functionality to minimize R&D iterations of dosing frequency and dose size
Provide real-time formulation support for adaptive clinical trials
Accommodate fragile molecules and particles to enable and speed the translation to final product scale
Produce first in-human dosage forms using 3DP technologies with powerful advantages over other early-stage approaches
White paper
REDEFINING FAST MELT FOR PHARMA
Download White paper

EARLY STAGE SOLUTIONS ACCELERATE TIME-TO-MARKET

From early-stage development to late-stage commercialization, our 3DP technologies provide formulation and manufacturing solutions that translate more quickly to final product scale, bringing significant business advantages to your bottom line.

Use breakthrough dosage form functionality to minimize R&D iterations of dosing frequency and dose size
Provide real-time formulation support for adaptive clinical trials
Accommodate fragile molecules and particles to enable and speed the translation to final product scale
Produce first in-human dosage forms using 3DP technologies with powerful advantages over other early-stage approaches
White paper
REDEFINING FAST MELT FOR PHARMA
Download White paper

EARLY STAGE SOLUTIONS ACCELERATE TIME-TO-MARKET

From early-stage development to late-stage commercialization, our 3DP technologies provide formulation and manufacturing solutions that translate more quickly to final product scale, bringing significant business advantages to your bottom line.

Use breakthrough dosage form functionality to minimize R&D iterations of dosing frequency and dose size
Provide real-time formulation support for adaptive clinical trials
Accommodate fragile molecules and particles to enable and speed the translation to final product scale
Produce first in-human dosage forms using 3DP technologies with powerful advantages over other early-stage approaches
White paper
REDEFINING FAST MELT FOR PHARMA
Download White paper